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OX40 stimulation is known to enhance activation of effector T cells and to inhibit induc-
tion and suppressive function of Treg. Here we uncovered a novel role of OX40 in
sustaining Treg competitive fitness in vivo, during repopulation of lymphopenic hosts and
reconstitution of BM chimeras. Defective expansion of OX40-null Treg diminished their
ability to suppress inflammation in a model of lymphopenia-driven colitis. OX40-mediated
promotion of Treg fitness spanned beyond lymphopenic environments, as endogenous
Treg in OX40-null mice showed decreased accumulation during thymic development,
enhanced susceptibility to antibody-mediated depletion and defective turnover following
thymectomy. In vitro, OX40-deficient Treg were found to be intrinsically hyporesponsive to
IL-2, in terms of Stat5 phosphorylation and proliferation, according to elevated SOCS1
content and reduced miR155 expression. Therefore, OX40 is a key factor in shaping Treg
sensitivity to IL-2 and promoting their proliferation and survival, toward accurate immune
regulation.
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Introduction
Treg are a specialized subset of CD41 T lymphocytes deputed to
maintain self-tolerance through inhibition of a variety of immune
responses [1]. Dysregulation in functions or numbers of Treg has
been associated to severe autoimmunity and inflammation in
both mice and humans. Treg selectively express the transcription
factor Foxp3, which determines their regulatory program, and
constitutively express the a-chain of the IL-2 receptor CD25,
which mediates their peripheral homeostasis.
Also, murine Treg constitutively express OX40 [2, 3], a
member of the Tumor Necrosis Factor-Receptor superfamily,
encoded by the Tnfrsf4 gene. OX40-null mice show defective
T-cell activation and impaired reactivity in multiple settings [4].
Indeed, this receptor intervenes at different checkpoints in
shaping optimal immune responses and in counteracting both
recessive and dominant tolerance. OX40, expressed on non-Treg
upon activation, conveys survival signals [5], promotes the
acquisition of effector functions [6], impedes and reverts T-cell
anergy [7] and even prevents the acquisition of a regulatory
phenotype under TGF-b exposure [8, 9] or under Tr1-promoting
conditions [10]. A further level of control is represented by the
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ability of OX40 triggering to inhibit Treg suppressive function
in vitro and in vivo, as shown in models of graft-versus-host
disease [3], colitis [2] and cancer immunotherapy [11, 12].
Recently we have found OX40 bridging the bidirectional inter-
action between Treg and mast cells, leading to blockade of
histamine degranulation and anaphylactic response on the mast
cell side [13] and to inhibition of suppressive activity on the Treg
side [14].
Little is known about the role of OX40 in Treg development
and homeostasis. Young Tnfrsf4/ mice show reduced numbers
of CD41CD251 cells in central and peripheral lymphoid organs
[2], though this observation has not been confirmed at the Foxp3
level. Lymphopenia-driven Treg proliferation is either decreased
or increased in OX40L-null or OX40L-transgenic hosts, respec-
tively, indicating a role for OX40 in enhancing Treg proliferation
in vivo [2], but the functional relevance of this finding remains
unexplored.
Crucial to Treg homeostasis is the IL-2 signal. In the absence
of IL-2 or IL-2 receptor, Treg still develop in the thymus but
display a profound defect in peripheral homeostasis [15]. Treg
developing from BM cells with impaired/absent IL-2 signal fail to
compete in vivo for IL-2 during the reconstitution of lethally
irradiated hosts [16, 17]. The transcription factor Stat5, activated
by IL-2, directly binds and induces Foxp3 [18]. On the other
hand, Foxp3 sustains IL-2 responsiveness by inducing miR155,
which inhibits at the post-transcriptional level SOCS1, a major
silencer of IL-2 signal [19].
The signals of OX40 and IL-2 cooperate during the differ-
entiation of conventional T cells into effector cells [20]; thus a
similar interaction may also participate in Treg homeostasis.
Indeed, we observed OX40 regulating the competitive fitness of
Treg in vivo during repopulation of lymphopenic hosts, recons-
titution of BM chimeras and suppression of inflammatory bowel
disease. Endogenous Treg in Tnfrsf4/ mice show altered accu-
mulation during thymic development, enhanced susceptibility to
depletion and defective turnover following thymectomy, suggest-
ing a role for OX40 in promoting Treg proliferation and survival in
non-lymphopenic environments. OX40 deficiency is associated
with a defective responsiveness to IL-2, in terms of STAT5 phos-
phorylation and cell proliferation. A higher SOCS1 level, due to a
reduced miR155 expression, could account for impaired IL-2
response of OX40-null Treg. Therefore, OX40 sustains Treg fitness
by lowering the threshold for IL-2 sensitiveness.
Results
OX40 promotes Treg competitive fitness in vivo
Lymphopenia-driven homeostatic proliferation is the suitable
context in which differences in Treg competitive fitness may
emerge. To study the direct competition between mature WT and
Tnfrsf4/ Treg in vivo, Rag1/ mice received WT CD45.1 Treg
mixed at 1:1 ratio with CD45.2 WT or Tnfrsf4/ Treg (Fig. 1A).
At day 20 after transfer, the CD45.1:CD45.2 proportion within
circulating Foxp31 cells was profoundly unbalanced in favor of
WT Treg when cotransferred with OX40-null but not with WT
counterparts (Fig. 1B). Time-course analysis of Treg frequency in
peripheral blood showed that Tnfrsf4/ Treg suffered the
competition with WT Treg starting day 6 after transfer and
progressively disappeared from the Treg compartment within the
following 2 wk (Fig. 1C and D, 18.9870.95 versus 35.6074.10 at
day 6, po0.005; 6.1871.09 versus 32.8873.40 at day 13,
po0.005; 5.2370.04 versus 35.1571.06 at day 20, po0.005).
The CD41Foxp3- cells contaminating the preparation of adop-
tively transferred cells (around 10%) extensively expanded in the
lymphopenic hosts so as to recover the physiological Treg
proportion, as previously reported [21]. We found no difference
in the homeostatic expansion between WT and Tnfrsf4/ non-
regulatory cells, indicating that OX40 signal enhanced competi-
tive fitness selectively in Treg (Fig. 1D, right). The analysis of
BrdU incorporation showed significantly lower division rate in
Tnfrsf4/ Treg compared with the WT control (8.7673.00
versus 18.3876.58, po0.05), indicating that the defective
competitiveness of Tnfrsf4/ Treg was mainly due to decreased
proliferation in response to lymphopenia (Fig. 1E and F).
The percentage of Brdu1 cells in the gated CD45.1 Treg
compartment did not differ when put in competition with WT
or with Tnfrsf4/ CD45.2 Treg counterpart (Fig. 1E and F).
Two reports have shown that, following BM transplantation,
host Treg surviving irradiation undergo extensive expansion, thus
competing with donor-derived Treg, during the reconstitution of
the normal Treg pool necessary to prevent lethal autoimmunity
[16, 22]. We analyzed the role of OX40 in the ability of deve-
loping donor Treg to compete with host residual cells by recon-
stituting lethally irradiated CD45.1 mice with T-cell-depleted BM
cells obtained from scurfy mice, mixed at 4:1 ratio with WT or
Tnfrsf4/ counterpart (Fig. 2A), using a previously described
approach [23] that allows, in this combination, to obtain the
totality of Treg from WT or Tnfrsf4/ BM while the majority of
non-regulatory cells from scurfy (OX40-competent) BM. After
8–12 wk, peripheral blood, LN and spleens of all the chimeras
showed a physiological Treg frequency (Fig. 2B). Based on the
congenic marker CD45.1, the Treg pool contained a significant
proportion of host radioresistant cells, which were OX40-positive,
as expected (Fig. 2B). However, Treg derived from a Tnfrsf4/
donor BM competed less efficiently with the OX40-expressing
CD45.1 host Treg than Treg from WT donor BM. Indeed, the
proportion of host:donor Treg shifted from 30:70 in scurfy:
WT>CD45.1 mice, to 50:50 in scurfy:Tnfrsf4/>CD45.1
chimeras (Fig. 2B and C, 6.07709% versus 8.7270.96% donor
Treg, po0.005; 5.5170.63% versus 3.5870.44% host Treg,
po0.01). The OX40 effect on Treg competitive fitness was cell-
intrinsic, as no OX40-deficient cells other than Treg were
underrepresented within the donor-derived compartment in
scurfy:Tnfrsf4/>CD45.1 chimeras. A kinetics experiment
showed that BM-derived Tnfrsf4/ Treg appeared in the
peripheral blood at the same time of WT Treg, but showed
defective competition to host Treg compared with the WT control
starting 7 wk after transplantation (Fig. 2D, left). Of note, the
Eur. J. Immunol. 2010. 40: 2902–2913 Immunomodulation 2903
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Foxp3-negative compartment was replaced with BM-derived cells
more efficiently than the Treg compartment and without differ-
ence between the two donor types, indicating again that OX40-
induced fitness was a Treg-restricted effect (Fig. 2D, right).
Thus, we have characterized the role of OX40 in sustaining
Treg competitive fitness during homeostatic proliferation.
Tnfrsf4/ Treg show reduced capacity to inhibit
lymphopenia-driven colitis
Adoptively transferred CD41CD45RBhigh T cells extensively
proliferate into lymphopenic hosts, so as to induce a Th1-
mediated inflammation mainly localized in the intestine and
resembling inflammatory bowel disease [24]. Injection of Treg at
the appearance of first signs of colitis results in symptoms
amelioration and resolution of inflammation [25]. Exogenous
Treg migrate to mesenteric LN, infiltrate colonic lamina propria,
proliferate massively and suppress dendritic cells and T cells
mainly through the local secretion of IL-10 [25, 26]. We took
advantage of this experimental model to test whether the
defective proliferation of Tnfrsf4/ Treg under lymphopenic
condition was biologically relevant in the resolution of estab-
lished colitis. Rag1/ mice repopulated with CD45.1 CD41
CD45RBhigh T cells, showing clinical signs of colitis such as weight
loss, piloerection, hunching and diarrhea after 13 days, were left
Figure 1. OX40 determines Treg competitive fitness in lymphopenia-induced proliferation. (A) Scheme of the experiment. WT CD45.1 Treg were
mixed at 1:1 ratio with WTor Tnfrsf4/ CD45.2 Treg and i.v. injected into Rag1/ mice. Resultant cell populations were analysed by flow cytometry
at the indicated times. (B) Representative histogram plots of CD45.1/CD45.2 frequency in gated CD41 Foxp31 Treg before injection and 20 days after
in vivo expansion. (C) Representative contour plots showing Foxp3 versus CD45.1 staining of circulating Treg. (D) Frequency of CD45.2 cells in
peripheral blood in the Treg (left) or non-Treg (right) compartments over time. (E) Representative plots of BrdU incorporation in CD45.1 or CD45.2
Treg in LN. (F) Pooled analysis of BrdU incorporation in CD45.1 or CD45.2 Treg in each experimental group. A mean 2.5-fold decrease in BrdU
incorporation was detected in Tnfrfs4/ as compared with WT Treg. Data are (B, C and E) representative or (D and F) mean7SD of four mice per
group. The experiment was repeated twice. po0.05, po0.005 (non-paired Student’s t test).
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untreated or received CD45.2 WT or Tnfrsf4/ Treg. While
untreated mice failed to resolve the disease, mice injected
with WT Treg showed clinical improvement and increased
body weight. On the contrary, Tnfrsf4/ Treg showed a
significantly lower ability to cure colitis, as recovery of the
initial body weight occurred with a significant delay (from
d23–d31 to d32–d41 interval) compared with WT Treg-cured
controls (Fig. 3A). On histopathological evaluation untreated
mice displayed a severe colitis (median score 4, mean score
3.5070.71) with marked disruption of the glandular epithelium,
profound reduction of the goblet cell number and intense
inflammatory infiltration involving both mucosa and submucosa.
Treatment with WT Treg achieved histological remission of the
colitis (median score 1, mean score 1.4070.47, po0.005
versus untreated po0.05 compared with Tnfrsf4/ Treg) since
treated mice showed only slight crypt hyperplasia, scant
leukocytic infiltration and normal to slightly reduced number of
goblet cells. Specimens of mice treated with Tnfrsf4/ Treg were
characterized by moderate hyperplasia of the crypts, reduced
number of goblet cells and considerable chronic inflammatory
infiltrate mainly involving the lamina propria (median score 2,
mean score 1.9370.78, po0.005), consistently with an inter-
mediate picture between untreated and WT Treg-treated mice.
Serum TNF-a, measured in the d32–d41 interval, was signifi-
cantly reduced in colitic mice, receiving WT but not Tnfrsf4/
Treg (175.847103.49 in untreated mice, versus 59.69738.71
with WT Treg, po0.05; versus 98.99776.06 with Tnfrsf4/ Treg,
p40.05 (Fig. 3B and C).
To correlate disease manifestation with Treg expansion, we
checked the frequency of Treg in peripheral blood at two differ-
ent time points during the resolution of colitis. As previously
reported, we found a sizeable population of Foxp31 cells carrying
the CD45.1 congenic marker, derived from the conversion into
Treg of non-regulatory precursors contained in the donor CD41
CD45RBhigh T cells [27]. Twenty-three days after colitis induc-
tion, when mice treated with WT Treg showed accelerated weight
gain compared with untreated and Tnfrsf4/ Treg-treated
controls, we found a higher frequency of Foxp31 cells in mice
injected with WT Treg than in untreated mice, the majority of
which comprised CD45.2 exogenous Treg (Fig. 3). On the
contrary, the fraction of Treg in mice injected with Tnfrsf4/
Treg was similar to that of untreated controls and contained a
majority of CD45.1 induced Treg (Fig. 3D, 57.66716.81%
CD45.2 Treg in the group treated with WT cells versus
37.1076.83% in the group treated with Tnfrsf4/ Treg,
po0.05). In contrast, at day 34, when mice treated with
Tnfrsf4/ Treg eventually started to ameliorate, CD45.2 Treg
expanded and outnumbered the CD45.1 counterpart without
difference with mice injected with WT Treg (Fig. 3D). High Treg
frequency was detected also in the mesenteric LN and in the
Figure 2. BM-derived OX40-null Treg compete less efficiently with host Treg in BM transplantation (A) Scheme of the experiment. CD45.1 mice
were lethally irradiated and reconstituted with T-cell-depleted scurfy BM mixed in a 4:1 ratio with T-cell-depleted Tnfrsf4/ or WT BM.
(B) Representative flow cytometry of CD4 and Foxp3 staining (left panels) and the phenotype and frequency of host-derived (CD45.2-OX401) and
BM-derived (CD45.21OX401 or OX40) cells in the gated Treg population (right panels) of LN cells from the two groups of BM chimeras.
(C) Frequency and composition of the Treg pool in terms of CD45.1/CD45.2 subsets in BM chimeras as compared with WT and Tnfrsf4/ controls.
Numbers indicate the mean percentage of CD45.1 or CD45.2 cells in each group. (D) Kinetics of cell repopulation in the peripheral blood of CD45.2
BM-derived Treg (left) and non-Treg (right). Data are (B) representative and (C-D) mean7SD of three to five mice per group. The experiment was
repeated five times. po0.05, po0.01, po0.005 (non-paired Student’s t test).
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lamina propria of mice treated with WT or OX40-null Treg, in
comparison to untreated mice (Fig. 3E). This suggests that OX40
plays a non-redundant role in early Treg expansion and colitis
suppression, and that other signals may overcome OX40 defi-
ciency and rescue Treg fitness and function at later time points.
Beside defective systemic expansion, impaired suppressive
function and/or suboptimal recruitment of OX40-null Treg
might concur to inefficient inhibition of colitis. Because of
the established role of Treg-derived IL-10 in suppressing
colitis [26], we tested whether Tnfrsf4/ Treg could have
defective suppressive function in vivo as a consequence of
reduced IL-10 production. IL-10 intracellular staining performed
in Treg re-populating mesenteric LN and colonic lamina propria
showed no relevant defect in IL-10 secretion in WT or Tnfrsf4/
Treg (Fig. 3E). To also investigate the possibility of a defective
recruitment of Tnfrsf4/ Treg to inflamed sites, Treg were
stained for CD103, a crucial integrin for gut homing and for
immune regulation in the colon [28, 29]. Both WT and OX40-null
Treg were found highly expressing CD103 without difference
(Fig. 3E).
Figure 3. OX40-null Treg have decreased ability to resolve colitis. Colitis was induced in Rag1/ mice by injecting sorted CD45.1 CD45RBhigh CD41
cells (day 0). At day 13 (arrow), mice were left untreated (nt) or received WT or Tnfrsf4/ Treg. (A) Kinetics of percent change in body weight (left;
mean7SD) and percent change in body weight grouped by time intervals (right; each symbol represents one mouse; short horizontal bar, the
mean). (B) Serum TNF-a levels on day 37 after colitis induction. (C) Histological grading of colitis on day 42. Colitis score per animal (left; horizontal
bar represents the mean) and representative H&E-stained sections from the distal portion of the colon (right). The inset shows cryptic abscesses.
Scale bars (white): 50 mm. Original magnifications: upper panels, 100 ; lower panels 200 ; inset 400 . (D) Frequency and proportions of
circulating CD45.1/CD45.2 Treg on day 20 or 34. Numbers indicate the mean percentage of CD45.1 or CD45.2 cells in each group. (E) Expression of
Foxp3 versus OX40, CD103 or IL-10 by mesenteric LN (MLN) and lamina propria (LP) cells. The experiment was repeated twice with four to five mice
per group. po0.05, po0.01, po0.005 (non-paired Student’s t test).
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OX40 governs Treg fitness in non-lymphopenic
contexts
BM transplantation and T-cell transfer in immunodeficient hosts
are characterized by extensive lymphopenia-driven proliferation,
a setting that although non-physiological may mirror some
therapeutic situations. Nevertheless, to address the contribution
of OX40 in shaping the endogenous Treg compartment in
immunocompetent mice, we analyzed the frequency of Foxp31
T cells in peripheral lymphoid organs and thymuses of WT and
Tnfrsf4/ mice at different ages. While no difference was found
in Treg frequency in LN (Fig. 4A and B) or spleens (data not
shown), CD4 single positive, but not double positive, thymocytes
of OX40-null animals contained a significantly lower percentage
of Foxp31 cells regardless of mouse age (Fig. 4A and B,
3.4670.41 versus 4.7770.44 at 2 wk, po0.01; 3.0370.50 versus
3.9870.55 at 4 wk, po0.05; 2.2570.36 versus 3.4070.25 at
8 wk, po0.01). We did not detect an altered expression level of
Foxp3 or CD25 in thymic or peripheral Treg in WT or Tnfrsf4/
mice at any age (data not shown). These results indicate that
OX40 may play a physiological role in Treg thymic expansion,
rather than in Treg lineage decision at the double positive stage.
The fitness signal triggered by OX40 in Treg may extend
beyond proliferation and directly affect their survival under
external pressures, for instance mediating their resistance to
depletion mediated by anti-CD25 mAb (PC61). Indeed, we
observed that Treg resisting PC61-mediated depletion displayed
higher expression of OX40 6 days after treatment than untreated
Treg (Supporting Information Fig. 1A and B, 127.50711.61
versus 82.2577.05, po0.005). Accordingly, Tnfrsf4/ Treg were
significantly more susceptible to depletion than WT Treg
(Supporting Information Fig. 1C and D, 4.9570.70 versus
6.6470.83% residual Treg, po0.005). We also checked the
response of WT and Tnfrsf4/ Treg to central depletion operated
by thymectomy. Three weeks after thymus removal, Treg
frequency was significantly lower in Tnfrsf4/ than WT mice
(14.1572.30 versus 16.7272.18, po0.05). The Treg decline in
Tnfrsf4/ versus WT mice was associated to significant increase
Figure 4. Role of OX40 in Treg thymic development. Treg frequency in thymuses and peripheral LN of WT and Tnfsrf4/ mice aged 2, 4 or 8 wk.
(A) Mean7SD of four mice per group and (B) representative plots of CD4 and Foxp3 staining at the indicated ages. DP, double positive thymocytes;
SP, CD4-single positive thymocytes. po0.05, po0.01 (non-paired Student’s t test).
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of apoptosis (4.1673.03 versus 1.6470.89% AnnexinV1 Treg,
po0.05) and decrease of proliferation (5.3871.56 versus
7.5672.06% BrdU1 Treg, po0.01), indicating a role for OX40 in
supporting Treg turnover in this context (Supporting Information
Fig. 2). In summary, OX40 supported the fitness of endogenous
Treg also in non-lymphopenic hosts, especially when Treg should
maximize the response to trophic factors, such as during thymic
development and depletion-induced peripheral expansion.
OX40 signal optimizes Treg responsiveness to IL-2
IL-2 is the main cytokine responsible for Treg fitness in vitro and
in vivo [30]. We hypothesized that the lower ability of Tnfrsf4/
Treg to expand in lymphopenic conditions might result from a
defective response to IL-2. WT and Tnfrsf4/ Treg were
stimulated in vitro with scaled doses of recombinant IL-2 and
stained for phosphorylated STAT5 after different time intervals.
STAT5 phosphorylation was lower in Tnfrsf4/ than in WT Treg,
following exposure to different concentrations of IL-2 (Fig. 5A).
This event was more pronounced after 5 or 10 min than after
1 min, suggesting that the defect of OX40-null Treg mainly affected
late and sustained, rather than immediate, IL-2 response (Fig. 5B).
To study whether impaired IL-2 response was correlated to
reduced proliferation, we exposed CFSE-labelled WT and
Tnfrsf4/ Treg to scaled concentrations of IL-2 in the presence
of TCR triggering. Without exogenous IL-2, Treg were completely
anergic, as previously described [31]. When IL-2 was present,
OX40-deficient Treg proliferated with lower efficiency compared
with their WT counterparts (Fig. 5C and D), in line with the
attenuated STAT5 phosphorylation. We checked the expression
level of CD25 in WT and Tnfrsf4/ Treg, freshly isolated ex vivo or
after in vivo expansion, without finding any difference (data not
shown). Therefore, we hypothesized that attenuated IL-2 respon-
siveness in OX40-null Treg might be due to an intrinsic defect in
the intracellular machinery leading to STAT5 signaling.
SOCS1 is one of the major inhibitors of STAT5 phosphoryla-
tion following engagement of IL-2 receptor [32]. Rudensky and
colleagues have recently demonstrated that increased expression
of SOCS1 is responsible for the diminished competitive fitness of
miR155/ Treg [19]. Indeed, Foxp3 directly induces miR155
that in turn silences SOCS1 expression, thus enhancing IL-2
Figure 5. Attenuated IL-2 signaling in OX40-deficient Treg. (A and B) Purified WT or Tnfrsf4/ Treg were left unstimulated or treated with
increasing doses of rIL-2 for the indicated times and phospho-Stat5 determined by flow cytometry. (A) Representative histograms (at 5 min with
2 IU/mL rIL-2) and (B) kinetics of Stat5 phosphorylation. (C and D) In vitro proliferation of WT or Tnfrsf4/ Treg after 72 h exposure to anti-CD3 and
increasing concentrations of rIL-2. (C) Representative plots of CFSE dilution at 72 h in gated CD41 Foxp31 Treg and (D) the proliferative response of
Treg to increasing doses of IL-2 doses. (E) Western blot of SOCS1 in purified Treg or non-regulatory cells (Teff), naive or activated for 3 days with
anti-CD3, obtained from WT or Tnfrsf4/ mice. Numbers indicate densitometric SOCS1 expression values normalized to b-actin expression values
and fold increase in SOCS1 expression in OX40-null cells compared with WT cells. (F) Quantitative Real-time RT-PCR of miR155, normalized to U6,
in WT or Tnfrsf4/ Treg. Every experiment was repeated twice with pooled Treg from five to ten mice per group. (A, B, C and E) Representative and
(D and F) mean7SD data of two experiments. po0.05, po0.01 (non-paired Student’s t test).
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signal [19]. To test whether the diminished fitness of Tnfrsf4/
Treg involved dysregulation in this pathway, we checked SOCS1
protein level in WT and Tnfrsf4/ Treg by Western blot. As
controls, naı¨ve and activated T cells were used, expected to
express high and low level of SOCS1, respectively. We found
Tnfrsf4/ Treg expressing an eight-fold higher SOCS1 level than
the WT counterpart, while no relevant differences were observed
in naı¨ve or activated T cells (Fig. 5E). In line with this result, real
time RT-PCR revealed diminished miR155 amounts in Tnfrsf4/
compared with WT Treg (0.8570.10 versus 1.2970.13, po0.01),
indicating that miR155 dysregulation may lie behind altered
SOCS1 expression and IL-2 response (Fig. 5F). These data indi-
cate that OX40-null Treg have an intrinsic defect in IL-2
responsiveness because of decreased miR155 content and
consequently enhanced SOCS1 expression.
Discussion
OX40 has emerged as a relevant molecule regulating Treg
suppressive functions. Several findings suggest that OX40 role
in Treg biology may reveal a higher degree of complexity than
previously expected [33]. Here we show that OX40 expression
has a non-redundant role in supporting Treg competitive fitness
in vivo in both lymphopenic and lymphoreplete environments.
The underpinning mechanism stems from a constitutive lower
sensitivity to IL-2, due to decreased miR155 content and
consequently increased SOCS1 expression.
Impaired competitive fitness of Tnfrsf4/ Treg resulted in
their lower efficiency to cure lymphopenia-driven colitis. Indeed,
in this model, extensive Treg proliferation occurs in vivo so as to
outnumber effector cells and resolve inflammation [25].
However, we cannot exclude that OX40 deficiency may
compromise also the intrinsic suppressive function of Treg. For
instance, we have shown that Treg suppress histamine degranu-
lation in mast cells through OX40 [13], and Khazaie and collea-
gues have demonstrated that adoptively transferred Treg inhibit
mastocytosis in colon polyposis [34], but very little is known
about involvement of this pathway in colitis development and
resolution. We have checked for IL-10 production, a critical factor
in colitis suppression [26, 35, 36], among lamina propria-infil-
trating Treg, and found no difference between OX40-proficient
and OX40-deficient Treg. Although we have previously shown a
similar surface phenotype in naı¨ve WT and OX40-null Treg [13],
we cannot exclude that other molecules, such as Pd-1, CTLA-4
and membrane-bound TGF-b, are differentially expressed in
Tnfrsf4/ Treg from inflamed tissues where they may become
relevant for Treg-intrinsic suppressive ability. However, expres-
sion of CTLA-4 or Pd-1 may not be exclusively interpreted as
function of Treg suppressive activity, being also associated to
Treg maintenance and expansion [37, 38]. However, defective
Treg recruitment into inflamed organs seems unlikely, WT and
Tnfrsf4/ Treg being present in comparable frequency and with
similar CD103 expression pattern in mesenteric LN and lamina
propria of cured mice.
When transferred at 1:1 ratio into Rag1/ mice, CD45.2
Tnfrsf4/ Treg were greatly outnumbered by the CD45.1 WT
counterpart and almost disappeared from lymphoid organs
(Fig. 1) including mesenteric LN and colonic lamina propria
(data not shown). Conversely, in Rag1/ mice receiving CD45.1
CD41 CD45RBhigh to induce colitis, the minority of CD45.1-
induced WT Treg initially dominate the competition with the
Tnfrsf4/ Treg given for therapeutic purpose, but lately the
Tnfrsf4/ Treg expanded and outcompeted the CD45.1 fraction.
The different outcome could be due to the starting proportion
and the nature of competitors that may shift the balance of
competition. Indeed OX40-null Treg compete with equal amounts
of natural Treg in the former setting, while with a minority of
induced Treg in the latter setting. Importantly, natural and
induced Treg display a genetically different program that may
affect their phenotypic stability in vivo [27].
Many data support the idea that OX40/OX40L drives inflam-
mation in different models of experimental colitis. Dendritic cells
highly express OX40L in the mesenteric LN of colitic mice [39].
Blockade of this axis by specific antibodies dramatically reduces
T-cell activation and development of colitis, induced by T-cell
transfer [39, 40] or dextran sulfate sodium [41]. Tnfrsf4/
T cells are not able to induce colitis into Rag2/ mice, and WT
T cells failed to induce colitis into OX40L-deficient Rag2/ mice,
observations that demonstrate that OX40 triggering is crucially
required for activation of colitogenic T cells [2]. On the other
hand, OX40 triggering inhibits Treg suppression, as demonstrated
by the finding that Treg cannot suppress colitis when cotrans-
ferred with T cells in transgenic immunodeficient mice expressing
OX40L ubiquitously and constitutively [2]. We add here that
Tnfrsf4/ Treg show diminished ability to cure established
colitis, because of an intrinsically defective lymphopenia-driven
proliferative response.
A previous report highlighted that young OX40-deficient
mice have lower counts of CD41CD251 T cells in both spleen
and thymus [2]. However, a more recent study with Foxp3gfp
knock-in mice did not highlight any major defect in Treg
frequency in lymphoid organs of OX40-KO mice [9]. According
to the latter, we found no difference in Treg frequency or
Foxp3 content in spleens or LN of WT and Tnfrsf4/
mice. Refined analysis of thymocytes revealed decreased
Treg percentage in CD4 single positive, but not double positive,
T cells in OX40-null mice. Indeed, OX40 is expressed by
developing thymocytes, particularly by Treg precursors,
mainly at the single positive stage [42]. OX40 induction in
Foxp31 thymocytes accompanies high TCR expression and may
even precede CD25 up-regulation [42]. Of note, the amount of
miR155 is largely expanded in single positive compared with
Foxp31 double positive thymocytes [19], indicating that optimal
IL-2 responsiveness, settled by OX40, CD25 and miR155 expres-
sion, intervenes in shaping Treg thymic pool without compro-
mising early Treg development. This defect is however
compensated in the periphery, likely because regulatory thymic
emigrants rapidly accumulate under peripheral homeostatic
control.
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Treg surviving depletion regimens based on polyclonal anti-
lymphocyte serum [43] or cyclophosphamide [12] express higher
levels of OX40 than the bulk untreated Treg population. We have
confirmed this finding in mice treated with the anti-CD25 anti-
body PC61, widely used to deplete Treg. PC61 fails to completely
eliminate Treg and down-regulates the expression of CD25 in
residual Treg [44]. According to previous findings regarding
depletion by polyclonal anti-lymphocyte serum [43], we found
OX40-null Treg more susceptible to PC61-induced depletion. We
could not formally distinguish whether Treg already expressing
high levels of OX40 were protected from depletion, whether Treg
surviving depletion up-regulate OX40 to maximize their fitness in
vivo or whether OX40-competent Treg proliferate more efficiently
in response to depletion. In thymectomized animals, both
increased apoptosis and decreased proliferation concurred to the
Treg decline observed in Tnfrsf4/ mice, suggesting that defec-
tive Treg response to fitness signals may, directly or indirectly,
compromise several aspects of their biological functions. OX40
appears an important signal in sustaining Treg expansion/survi-
val, especially in condition of suboptimal sensitiveness to IL-2
because of down-regulation of the CD25 molecule. However, the
sole OX40 deficiency was not sufficient to allow complete Treg
depletion following PC61 treatment, suggesting that other signals
may contribute to Treg survival to depletion.
OX40 triggering has been interpreted so far as a counter-
regulatory mechanism, as it prevents TGF-b-induced Treg
development and counteracts Treg suppressive function. We have
found here that OX40-null Treg show attenuated fitness and
decreased colitis suppression, attributing to OX40 a key role in
promoting immune regulation. Apparently, the same signal that
inhibits Treg function sustains their fitness in vivo. An explanation
may be that Tnfrsf4/ Treg have intrinsic defects in their fitness,
possibly due to an altered transcriptional program established
during thymic development. Indeed, we found Tnfrsf4/ Treg
intrinsically hyporesponsive to IL-2 in vitro, in the absence of an
OX40 triggering signal. Therefore, pharmacological or genetic
OX40 triggering on mature WT Treg may inhibit their suppressive
function, while genetic OX40-deficiency may lead to impaired
Treg fitness. The cytokine context in which OX40 engagement
occurs may dictate the outcome of stimulation. Indeed, it could
be proposed that in homeostatic conditions dominated by IL-2,
such as thymic development and lymphopenia-induced prolif-
eration, OX40 enhances Treg susceptibility to IL-2 thus promot-
ing Treg fitness; conversely, in inflammatory conditions
dominated by proinflammatory cytokines, OX40 may expose Treg
to microenvironmental cues subverting their regulatory program.
This hypothesis requires further investigation, especially in rela-
tion to Foxp3 expression level in Treg following OX40 engage-
ment: we could not find any difference in Foxp3 protein amount
in WT or Tnfrsf4/ Treg, while others have observed decreased
Foxp3 content at both mRNA and protein level in OX40-triggered
Treg [9].
The context of OX40 engagement could also dictate whether
intratumoral Treg will be simply inhibited or even eliminated by
an OX40 agonist. We have showed that tumor-infiltrating Treg
express higher levels of OX40 compared with systemic Treg and
that intratumoral injection of an OX40 agonist induced tumor
rejection through the inhibition of Treg suppression [14].
Conversely, others have shown that, following cyclopho-
sphamide-based Treg depletion, OX40 is further up-regulated on
survived Treg and locally conveys death signals as a result of
hyper-activation [12]. It could be speculated that OX40 effects on
Treg may span from fitness to inhibition to death in different
contexts.
IL-2 regulates the intratumoral balance between Treg
and Th17 cells, favouring the former and counterbalancing
the latter [45]. Stat5 phosphorylation may dictate the balance
between the two lineages, constraining Th17 skewing [46]
while supporting Foxp3 expression [18]. OX40 may thus play a
role in the Th17-Treg balance in pathological conditions such as
cancer and autoimmunity. In a mouse model of CNS-directed
autoimmunity, OX40 expression can be detected on Th17
cells [14].
We have recently shown that Treg directly suppress mast cell
degranulation through OX40 [13]. This observation further
supports the idea that this molecule may play different roles in
Treg suppressive function, depending on the kind of target cells,
the strength of stimulation, the cytokine microenvironment, the
stability of Foxp3-induced program and the expression of other
costimulatory molecules [33]. Intrinsic to the costimulatory
nature of OX40 is the fact that, in all the aforementioned
contexts, its engagement does not provide an on/off switching
effect, but rather a fine-tuning of the cellular response to external
challenges.
Materials and methods
Mice and treatments
C57BL/6 WT mice were purchased from Charles River (Italy).
C57BL/6 CD45.1-congenic mice and Rag1/ mice were from
Jackson Laboratories. C57BL/6 OX40-deficient mice (Tnfrsf4/)
were from Nigel Killeen (UCSF). Scurfy mice were from Anna
Villa (HSR-TIGET, Milan, Italy). Mice were maintained under
pathogen-free conditions at the animal facility of Fondazione
IRCCS ‘‘Istituto Nazionale dei Tumori’’. Animal experiments were
authorized by the Institute Ethical Committee and performed in
accordance with institutional guidelines and national law
(DL116/92). In vivo systemic administration of anti-CD25 mAb
(PC61; hybridoma provided by V. Bronte, Padua, Italy) was
performed as previously described [11, 13].
Treg purification and adoptive transfer
Total splenocytes were enriched for T lymphocytes by passing
cells on nylon wool columns (Kisker). CD81 and B2201 cells
were removed using anti-CD8 and anti-B220 microbeads
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(Miltenyi Biotec). CD41CD251 cells were then separated using
the CD251 T-cell isolation kit (Miltenyi Biotec), according to the
manufacturer’s instructions. Flow cytometry showed that the
separate fractions were 90% pure from both WT and Tnfrsf4/
mice. A total of 4 105 CD45.1 WT Treg were mixed with equal
amount of CD45.2 WT or Tnfrsf4/ Treg and i.v. injected into
Rag1/ mice.
BM transplantation
BM cells were obtained by flushing the cavity of femurs from
donor mice. T-cell depletion was performed by magnetic
separation with anti-CD5 microbeads (Miltenyi Biotec). Cells
from scurfy male mice were mixed at 4:1 ratio with CD45.2
WT or Tnfrsf4/ cells. CD45.1 B6-recipient male mice were
lethally g irradiated with 1000 cGy (given as a split dose
5001500 cGy with a 3-h interval). After 2 h, mice were injected
i.v. with 6–9106 mixed BM cells. Recipient mice received
0.4 mg/mL gentalyn in the drinking water starting 1 wk before
irradiation and maintained thereafter.
In vivo BrdU incorporation and staining
Mice were injected i.p. once with 1 mg of BrdU (Sigma-Aldrich)
and then given 0.8 mg/mL BrdU in drinking water for 3 days.
LN and spleen cells were surface stained, fixed with Fix/Perm
buffer (eBioscience) and then analyzed using the BrdU Flow
kit (BD Pharmingen). Antibodies to BrDU (BD Pharmingen)
and Foxp3 (eBioscience) were added simultaneously to permea-
bilized cells.
Induction, cure and analysis of colitis
T cells, obtained from CD45.1 WT mice by passing spleens on
nylon wool columns (Kisker), were enriched for CD41 by
negative selection through magnetic separation with anti-CD8
and anti-B220 microbeads (Miltenyi Biotec). Cells were stained
with FITC anti-CD45RB (16A, eBioscience) and CD45RBhigh cells
were sorted on a FACSAria (Becton Dickinson). Purity was
499%. A total of 5105 sorted cells were i.p. injected into
Rag1/ mice. Weight loss appeared after 1–2 wk, accompanied
by diarrhea and piloerection. At day 13, colitic mice were left
untreated or received 1.4106 Treg, purified from CD45.2 WT or
Tnfrsf4/ donors by magnetic separation as described above.
Changes in body weight and clinical symptoms were monitored
every 1–2 days. Serum was collected at day 37 upon colitis
induction and TNF-a was measured by ELISA (eBioscience).
Formalin-fixed, paraffin-embedded colon sections were stained
with H&E and colitis severity was graded according to a four-
grade semi-quantitative scoring system. T cells were obtained
from mesenteric LN and lamina propria as previously described
[26] and analyzed by flow cytometry.
In vitro proliferation assay
Purified CD41CD251 cells were labelled by incubation with 5mM
CFSE (Invitrogen) in complete medium containing 10% FBS for
15 min at 371C. A total of 5 104 CD41CD251 cells were
cultured with 5 104 accessory cells (consisting of irradiated
splenocytes) in the presence of 1mg/mL of soluble anti-CD3
(e-Bioscience) in complete medium containing RPMI 1640
(Sigma-Aldrich) supplemented with 10% FCS, 2 mM L-glutamine,
200 U penicillin and 200 mg/mL streptomycin (Sigma-Aldrich).
Where indicated, recombinant IL-2 (Proleukin) was added at
scaled concentrations. Every condition was assayed in triplicate
and analysed after 72 h by flow cytometry after gating on CD41
Foxp31 cells.
Western blot
Fresh Treg, naı¨ve and activated CD41 T cells were lysed with a
chilled lysis buffer (50 mM Hepes, pH 7.0, 0.1% NP-40, 250 mM
NaCl, 1 Protease Inhibitor Cocktail). Cell debris was removed
by centrifugation at 14 000 rpm for 20 min at 41C. Solubilized
proteins were separated using SDS-PAGE and transferred to a
PVDF membrane. SOCS1 and b-actin were visualized using the
antibodies 4H1 (Invitrogen) and A2066 (Sigma), respectively.
Densitometric analysis was performed using NIH Image J
software.
Real time RT-PCR
Fifty nanograms of total RNA, isolated by using the mirVana
miRNA isolation kit (Ambion), were subjected to reverse
transcription according to the manufacturer’s instructions
(Applied Biosystems). Quantitative real time RT-PCR analysis
for miR155 was performed according to the TaqMan MicroRNA
Assays (Applied Biosystems) and samples normalized by evaluat-
ing RNU6 expression. Results were obtained using the compara-
tive Ct method.
Antibodies and flow cytometry
PE-Cy7 anti-CD4 (RM4-5), FITC anti-CD8 (53-6.7), FITC anti-
CD25 (PC61), PE anti-OX40 (OX86), FITC anti-CD45.1 (A20),
FITC anti-CD45.2 (104), PE anti-CD103 (2E7) were purchased
from eBioscience. Surface staining was performed by incubating
antibodies at 5mg/mL on ice for 30 min in PBS containing 2%
FBS. Intracellular staining with PE or APC anti-Foxp3 (FJK-16s)
was performed according to manufacturer’s instructions
(eBioscience). For IL-10 and Foxp3 staining, cells obtained
from LN and colonic lamina propria were stimulated with
50 ng/mL PMA, 500 ng/mL ionomycin (Sigma-Aldrich) with
Monensin (eBioscience) for 4 h at 371C, fixed in Fix/Perm
buffer (eBioscience) and stained with APC anti-Foxp3 and PE
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anti-IL-10 (JES5-16E3, eBioscience). To evaluate Stat5 phosphor-
ylation, Treg were stimulated with rIL-2 (Proleukin) and stained
with AlexaFluor488 anti-Stat5 pY694 (clone 47) according to the
manufacturer’s instructions (BD Bioscience). Flow cytometry
data were acquired on a FACSCalibur (Becton Dickinson) and
analysed with FlowJo software (version 8.8.4; Treestar).
Statistical analysis
Results are expressed as the means7SD. Data were analyzed
using a nonpaired Student’s t test (Prism software, GraphPad).
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